Page last updated: 2024-09-03

sc 58125 and cgs 15943

sc 58125 has been researched along with cgs 15943 in 1 studies

Compound Research Comparison

Studies
(sc 58125)
Trials
(sc 58125)
Recent Studies (post-2010)
(sc 58125)
Studies
(cgs 15943)
Trials
(cgs 15943)
Recent Studies (post-2010) (cgs 15943)
93015139028

Protein Interaction Comparison

ProteinTaxonomysc 58125 (IC50)cgs 15943 (IC50)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)0.97
Adenosine receptor A3Homo sapiens (human)0.406
Adenosine receptor A1Rattus norvegicus (Norway rat)0.006
Adenosine receptor A3Rattus norvegicus (Norway rat)0.0607
Adenosine receptor A2aHomo sapiens (human)0.012
Adenosine receptor A2bHomo sapiens (human)0.6304
Adenosine receptor A2bRattus norvegicus (Norway rat)0.0028
Adenosine receptor A2aRattus norvegicus (Norway rat)0.0029
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)1.28
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)8.48
Casein kinase I isoform alphaHomo sapiens (human)0.82
Casein kinase I isoform deltaHomo sapiens (human)0.24
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)0.11
Casein kinase I isoform epsilonHomo sapiens (human)0.49
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)0.14

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y1

Other Studies

1 other study(ies) available for sc 58125 and cgs 15943

ArticleYear
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
    Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:9

    Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation

2014